Stock Report

Indrayani Biotech Limited Finalizes Terms for ₹49.90 Crore Rights Issue

Posted On : 2026-04-10 10:31:42( TIMEZONE : IST )

Indrayani Biotech Limited (BSE: 526445), a Chennai-based diversified company, has officially announced the definitive terms and timeline for its upcoming Rights Issue. Following a meeting of the Rights Issue Committee on April 9, 2026, the company confirmed its plan to issue over 3.25 crore equity shares to existing shareholders to raise a total of ₹49.90 crore.

Strategic Structure and Pricing

The company has opted for a "partly paid-up" structure, which offers financial flexibility to participating shareholders. The total Rights Issue price is set at ₹15 per share, which includes a face value of ₹10 and a premium of ₹5.

Under the phased payment plan, investors are required to pay ₹3.75 per share at the time of application. This initial payment covers ₹2.50 of the face value and ₹1.25 of the premium. The remaining balance of ₹11.25 per share will be collected through one or more subsequent "calls" as determined by the company's committee in the future.

Entitlement and Shareholder Impact

The Rights Issue is offered at a ratio of 5:7. This means that for every 7 fully paid-up equity shares held by an eligible shareholder as of the record date, they are entitled to purchase 5 new rights shares.

To determine eligibility, the company has fixed Tuesday, April 28, 2026, as the Record Date. If the issue is fully subscribed and all subsequent call monies are paid, the company's total outstanding equity capital will expand significantly from approximately 4.55 crore shares to over 7.80 crore shares.

Key Execution Timeline

The Rights Issue is scheduled to open for subscription on Wednesday, May 27, 2026. Shareholders who do not wish to subscribe to their entitlements have the option to trade or renounce them during the "on-market renunciation period," which runs from the opening date until June 16, 2026. The entire issue will officially close on Thursday, June 25, 2026.

Regulatory and Monitoring Framework

To ensure transparency and proper utilization of the proceeds, Indrayani Biotech has appointed India Ratings and Research Private Limited as the monitoring agency. Axis Bank will serve as the Banker to the Issue. The company has already initiated the process with NSDL and CDSL to credit the rights entitlements directly into the demat accounts of eligible shareholders under a separate ISIN prior to the launch.

This capital infusion marks a pivotal step for Indrayani Biotech as it seeks to strengthen its balance sheet and fund its next phase of corporate growth.

Shares of INDRAYANI BIOTECH LTD. was last trading in BSE at Rs. 10.89 as compared to the previous close of Rs. 10.20. The total number of shares traded during the day was 197683 in over 300 trades.

The stock hit an intraday high of Rs. 11.30 and intraday low of 10.20. The net turnover during the day was Rs. 2110811.00.